Outcomes of Antiretroviral Therapy in Vietnam: Results from a National Evaluation

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Nguyen, Duc Bui ^a   Do, Nhan Thi ^b   Shiraishi, Ray W ^c   Le, Yen Ngoc ^a   Tran, Quang Hong ^d   Huu Nguyen, Hai ^b   Medland, Nicholas ^a   Nguyen, Long Thanh ^b   Struminger, Bruce Baird ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b MINISTRY OF HEALTH   (Viet Nam)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d HANOI UNIVERSITY OF PUBLIC HEALTH   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; EPIDEMIC; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAMED GROUPS OF PERSONS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PEOPLE WHO INJECT DRUG; POPULATION RESEARCH; PROBABILITY; RANDOMIZATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; VIET NAM; WORLD HEALTH ORGANIZATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIETNAM;

EID: 84874023462     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055750     Document Type: Article

References (38)

1. National Committee for AIDS, Drugs, and Prostitution Prevention and Control (2012) Viet Nam AIDS Response Progress Report 2012.
2. Vietnam Administration of HIV/AIDS Control (2012) Vietnam HIV/AIDS Estimates and Projections: 2011-2015 (under publication).
3. Ministry of Health (2009) National Guidelines for Diagnosis and Treatment of HIV/AIDS. Ministry of Health.
4. Rubin DB (1987) Multiple imputation for nonresponse in surveys. New York: Wiley. xxix, 258 p.
5. Royston P, (2004) Multiple imputation of missing value. The Stata Journal 4: 227-241.
6. Royston P, (2005) Multiple imputation of missing values: update. The Stata Journal 5: 188-201.
7. Royston P, (2005) Multiple imputation of missing values: update of ice. The Stata Journal 5: 527-536.
8. Royston P, Carlin JB, White IR, (2009) Multiple imputation of missing values: new features for mim. The Stata Journal 9: 252-264.
9. White IR, Royston P, (2009) Imputing missing covariate values for the Cox model. Stat Med 28: 1982-1998.
10. Duc Nguyen, Nhan Do, Ray Shiraishi, Yen Le, Quang Tran, et al. (2011) Outcomes of antiretroviral therapy in Vietnam: results from the 2010 national survey of adult patients starting therapy between 2005-2009. 10th International Congress on AIDS in Asia and the Pacific. Busan, Korea.
11. Auld AF, Mbofana F, Shiraishi RW, Sanchez M, Alfredo C, et al. (2011) Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One 6: e18453.
12. Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, et al. (2010) Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 24: 563-572.
13. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, et al. (2006) Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20: 1181-1189.
14. Lowrance DW, Ndamage F, Kayirangwa E, Ndagije F, Lo W, et al. (2009) Adult clinical and immunologic outcomes of the national antiretroviral treatment program in Rwanda during 2004-2005. J Acquir Immune Defic Syndr 52: 49-55.
15. May M, Boulle A, Phiri S, Messou E, Myer L, et al. (2010) Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 376: 449-457.
16. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, et al. (2007) Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 21: 2483-2491.
17. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296: 782-793.
18. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, et al. (2006) Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 20: 2355-2360.
19. Zhang F, Dou Z, Ma Y, Zhao Y, Liu Z, et al. (2009) Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 151: 241-251, W-252.
20. Mojumdar K, Vajpayee M, Chauhan NK, Mendiratta S, (2010) Late presenters to HIV care and treatment, identification of associated risk factors in HIV-1 infected Indian population. BMC Public Health 10: 416.
21. Chasombat S, McConnell MS, Siangphoe U, Yuktanont P, Jirawattanapisal T, et al. (2009) National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr 50: 506-512.
22. Severe P, Leger P, Charles M, Noel F, Bonhomme G, et al. (2005) Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 353: 2325-2334.
23. Rosen S, Fox MP, Gill CJ, (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4: e298.
24. Ministry of Health (2008-2011) HIV Sentinel Surveillance.
25. Morris JD, Golub ET, Mehta SH, Jacobson LP, Gange SJ, (2007) Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts. AIDS Res Ther 4: 12.
26. Moore RD, Keruly JC, Chaisson RE, (2004) Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr 35: 46-51.
27. Malta M, Bastos FI, da Silva CM, Pereira GF, Lucena FF, et al. (2009) Differential survival benefit of universal HAART access in Brazil: a nation-wide comparison of injecting drug users versus men who have sex with men. J Acquir Immune Defic Syndr 52: 629-635.
28. Muga R, Ferreros I, Langohr K, de Olalla PG, Del Romero J, et al. (2007) Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. AIDS 21: 2521-2527.
29. Solomon SS, Srikrishnan AK, Mehta SH, Vasudevan CK, Murugavel KG, et al. (2008) High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr 49: 327-332.
30. Solomon SS, Hawcroft CS, Narasimhan P, Subbaraman R, Srikrishnan AK, et al. (2008) Comorbidities among HIV-infected injection drug users in Chennai, India. Indian J Med Res 127: 447-452.
31. Grigoryan A, Hall HI, Durant T, Wei X, (2009) Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996-2004. PLoS One 4: e4445.
32. Wolfe D, Carrieri MP, Shepard D, (2010) Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 376: 355-366.
33. Dronda F, Zamora J, Moreno S, Moreno A, Casado JL, et al. (2004) CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use. AIDS 18: 2210-2212.
34. Wood E, Kerr T, Zhang R, Guillemi S, Palepu A, et al. (2008) Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users. HIV Med 9: 503-507.
35. Dalal RP, Macphail C, Mqhayi M, Wing J, Feldman C, et al. (2008) Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in johannesburg, South Africa. J Acquir Immune Defic Syndr 47: 101-107.
36. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, et al. (2010) Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr 53: 405-411.
37. Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, et al. (2007) True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bull World Health Organ 85: 550-554.
38. Brinkhof MW, Pujades-Rodriguez M, Egger M, (2009) Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 4: e5790.